12 completed, 6 withdrawn, 1 terminated, 1 unknown. 20 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 20 | Completed 12, Withdrawn 6, Terminated 1, Unknown 1 |
Follow Standard Therapy: new trials by email Literature Review of Standard Therapy trials Research Report on Standard Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults Mexidol, Standard Therapy - Vascular Cognitive Impairment no Dementia | Phase 4 | Completed | Pharmasoft | 120 | 2025-09-14 | 2026-07-14 |
| Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients Best Practice, Electronic Health Record Review, Interview - Advanced Malignant Solid Neoplasm, Delirium | Phase 4 | Withdrawn | Mayo Clinic | 2025-02-26 | 2025-05-01 | |
| The Efficacy of Self-Manufactured 40% Dextrose Gel in Asymptomatic Transient Neonatal Hypoglycemia Treatment self-manufactured 40% dextrose gel, Standard therapy - Neonatal Hypoglycemia | Phase 4 | Completed | Universitas Indonesia | 133 | 2023-05-01 | 2025-06-11 |
| Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients Ambroxol Hydrochloride, Standard Therapy - Severe Pneumonia, Community-acquired Pneumonia | Phase 4 | Completed | National University of Malaysia | 32 | 2023-01-07 | 2023-12-27 |
| Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. Aerosolized 13 cis retinoic acid plus Vitamin D, Aerosolized All trans retinoic acid plus Vitamin D, Standard therapy - Post COVID-19 Anosmia (Loss of Smell) | Phase 4 | Unknown | Kafrelsheikh University | 10000 | 2021-11-01 | 2021-11-11 |
| Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) Belimumab, Standard therapy - Systemic Lupus Erythematosus | Phase 4 | Completed | GlaxoSmithKline | 67 | 2021-10-21 | 2026-05-11 |
| Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension, Standard Therapy - Covid19 | Phase 4 | Completed | Epitech Group SpA | 40 | 2020-10-23 | 2021-08-25 |
| Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules, Placebo microgranules 1800mg, Standard Therapy - Fibromyalgia | Phase 4 | Completed | Epitech Group SpA | 21 | 2020-07-16 | 2023-09-07 |
| Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome Bupivacaine Liposome Injection, Standard Therapy - Osteoarthritis of the Shoulder, Shoulder Pain | Phase 4 | Withdrawn | University of Massachusetts, Worcester | 2019-12-09 | 2022-07-06 | |
| A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI hydration plus rosuvastatin therapy, Standard therapy - Contrast-induced Acute Kidney Injury, ST Elevation Myocardial Infarction | Phase 4 | Withdrawn | Shenyang Northern Hospital | 2019-02-20 | 2019-09-19 | |
| Adjunctive 5% Lidocaine Patches for Acute Non-radicular Low Back Pain in Emergency Department Patients lidocaine 5% patch, standard therapy, Non-medicated patch - Low Back Pain | Phase 4 | Withdrawn | Cook County Health | 2017-03-10 | 2023-06-29 | |
| SMOFLipid in Patients Who Are Intralipid Intolerant SMOFLipid, Standard therapy - Home Parenteral Nutrition, Short Bowel Syndrome | Phase 4 | Withdrawn | Mayo Clinic | 2017-02-01 | 2018-03-22 | |
| Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers Varenicline, BASC, Standard treatment - Nicotine Dependence, Major Depressive Disorder | Phase 4 | Completed | Northwestern University | 300 | 2015-07-24 | 2021-07-29 |
| EARly Prevention of aTHeroma Progression Standard Therapy, Rosuvastatin - Coronary Arteriosclerosis | Phase 4 | Terminated | CHEOL WHAN LEE, M.D., Ph.D | 111 | 2014-06-01 | 2018-06-25 |
| Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy - Systemic Lupus Erythematosus | Phase 4 | Completed | Human Genome Sciences Inc., a GSK Company | 503 | 2013-02-19 | 2021-09-08 |
| Belimumab Assessment of Safety in SLE Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy - Systemic Lupus Erythematosus | Phase 4 | Completed | GlaxoSmithKline | 4019 | 2012-11-27 | 2024-07-15 |
| Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Zoledronic acid, Standard Therapy - First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis | Phase 4 | Completed | Novartis Pharmaceuticals | 44 | 2010-06-01 | 2014-05-20 |
| Radical Prostatectomy and Perioperative Fluid Therapy Standard therapy, Maximization of cardiac stroke volume with fluid infusion - Prostate Cancer | Phase 4 | Completed | Copenhagen University Hospital, Rigshospitalet | 44 | 2008-10-01 | 2012-10-22 |
| Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study Benzathine penicillin G intramuscular 7.2 million units, Benzathine penicillin G intramuscular 2.4 million units - Syphilis | Phase 4 | Completed | Baylor College of Medicine | 64 | 2008-09-01 | 2016-05-17 |
| Ziprasidone vs Standard Therapy for Agitated Patients in the ED ziprasidone, Standard therapy - Psychosis, Agitation | Phase 4 | Withdrawn | George Washington University | 2008-09-01 | 2017-09-25 |
Lupus Erythematosus, Systemic (3) · Autoimmune Diseases (2) · Delirium (2) · Agnosia (1) · Anosmia (1) · Breast Neoplasms (1) · COVID-19 (1) · Cigarette Smoking (1) · Cognitive Dysfunction (1) · Community-Acquired Pneumonia (1) · Coronary Artery Disease (1) · Critical Illness (1) · Depressive Disorder, Major (1) · Fibromyalgia (1) · Healthcare-Associated Pneumonia (1)
Epitech Group SpA (2) · GlaxoSmithKline (2) · Mayo Clinic (2) · Baylor College of Medicine (1) · CHEOL WHAN LEE, M.D., Ph.D (1) · Cook County Health (1) · Copenhagen University Hospital, Rigshospitalet (1) · George Washington University (1) · Human Genome Sciences Inc., a GSK Company (1) · Kafrelsheikh University (1) · National University of Malaysia (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · Pharmasoft (1) · Shenyang Northern Hospital (1)
United States (9) · China (3) · Italy (3) · Brazil (2) · Colombia (2) · Indonesia (2) · Malaysia (2) · Russia (2) · South Korea (2) · Argentina (1) · Australia (1) · Bulgaria (1) · Canada (1) · Chile (1) · Croatia (1)
Alexander Chan, MD (1) · Brian Hitsman, Ph.D. (1) · Enrico Polati, MD (1) · Jose A Serpa-Alvarez, MD (1) · Mahmoud Elkazzaz, M.Sc of Biochemistry (1) · Manpreet S Mundi (1) · Prof.ssa Flaminia Coluzzi, MD (1) · Regina M. Mackey, MD (1) · Tamer Haydara, Ass/Prof of Internal medicine (1) · Yaling Han, MD (1)
PMID 21357346, PMID 22727868, PMID 24075361, PMID 25819173, PMID 25957977, PMID 26500974, PMID 27441006, PMID 27605513, PMID 28200045, PMID 28364046, PMID 28764827, PMID 29579758, PMID 29702618, PMID 31556318, PMID 33107014, PMID 33489995, PMID 33752207, PMID 34164944, PMID 34353586, PMID 34531304, PMID 34627324, PMID 36792172, PMID 37069490, PMID 37119868, PMID 37934573, PMID 37943674, PMID 38279368, PMID 38724182, PMID 38775637, PMID 39115551, PMID 39208825, PMID 8466261
R01CA184211 (1)